Purchase this article with an account.
Adriano Guarnieri, Alfonso Luis Sabater, Alvaro Velazquez-Villoria, Javier Moreno-Montanes; Evaluation of Meibomian Gland Morphology and Function in Patients Treated with Anti-glaucomatous Eye Drops. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1487.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze the effect of anti-glaucomatous topical treatments on the morphology and function of meibomian glands
This is a cross-sectional observational study of 45 patients with glaucoma treated with anti-glaucomatous eye drops and 20 patients without any topical eye drop treatment. Both groups were of similar ages. Glaucomatous patients had been treated with anti-glaucomatous eye drops for more than one year. We have analyzed the following parameters: number of anti-glaucomatous treatments, number of eye drops per day and number of treatments that contained benzalkonium chloride. Additionally, we performed the following tests: Schirmer test, tear break-up time test, slitlamp biomicroscopy analysis of the ocular surface and non-contact meibography (Meibom-Pen, JFC) of the upper eyelid
No differences were observed in the Schirmer test results between both groups. Tear break-up time was shorter in patients treated with anti-glaucomatous eye drops (p<0.05). Additionally, this group presented a higher degree of superficial punctate keratopathy (p<0.05), specially those patients with more than one medication. Meibomian gland depletion in the upper eyelid was also higher in this group (p<0.05)
Anti-glaucomatous topical treatments affect the meibomian gland morphology (tortuosity and length) and function. Additionally, they decrease the total area of meibomian glands in the upper eyelid
This PDF is available to Subscribers Only